Abstract：
BACKGROUND: ITPR1 is a key gene for autophagy, but its biological function is still unclear, and there are few studies on the correlation between ITPR1 gene expression and the occurrence and development of breast cancer.
METHODS: Analyze the expression of ITPR1 through online databases such as Oncomine and TIMER. Kaplan-Meier plotter and other databases were used to evaluate the impact of ITPR1 on clinical prognosis. The expression of ITPR1 in analysis of 145 cases of breast cancer and 30 cases of adjacent normal tissue was detected by Immunohistochemistry. Statistical analysis was used to evaluate the clinical relevance and prognostic significance of abnormally expressed proteins. And the Western Blot was used to detect the expression of ITPR1 between breast cancer tissues and cells. The TIMER database studied the relationship between ITPR1 and cancer immune infiltration. And used the ROC plotter database to predict the response of ITPR1 to chemotherapy, endocrine therapy and anti-HER2 therapy in patients with breast cancer.
RESULTS: Compared with normal breast samples, ITPR1 was significantly lower in patients with breast cancer. And the increased expression of ITPR1 mRNA was closely related to longer overall survival (OS), distant metastasis free survival (DMFS), disease specific survival (DSS) and relapse free survival (RFS) in breast cancer. And the expression level of ITPR1 was higher in patients treated with chemotherapy than untreated patients. In addition, the expression of ITPR1 was positively correlated with related gene markers of immune cells in different types of breast cancer, especially with BRCA basal tissue breast cancer.
CONCLUSIONS: ITPR1 was lower expressed in breast cancer. The higher expression of ITPR1 suggested favorable prognosis for patients. ITPR1 was related to the level of immune infiltration, especially in BRCA-Basal patients. All research results indicated that ITPR1 might affect breast cancer prognosis and participate in immune regulation. In short, ITPR1 might be a potential target for breast cancer therapy.
METHODS: Analyze the expression of ITPR1 through online databases such as Oncomine and TIMER. Kaplan-Meier plotter and other databases were used to evaluate the impact of ITPR1 on clinical prognosis. The expression of ITPR1 in analysis of 145 cases of breast cancer and 30 cases of adjacent normal tissue was detected by Immunohistochemistry. Statistical analysis was used to evaluate the clinical relevance and prognostic significance of abnormally expressed proteins. And the Western Blot was used to detect the expression of ITPR1 between breast cancer tissues and cells. The TIMER database studied the relationship between ITPR1 and cancer immune infiltration. And used the ROC plotter database to predict the response of ITPR1 to chemotherapy, endocrine therapy and anti-HER2 therapy in patients with breast cancer.
RESULTS: Compared with normal breast samples, ITPR1 was significantly lower in patients with breast cancer. And the increased expression of ITPR1 mRNA was closely related to longer overall survival (OS), distant metastasis free survival (DMFS), disease specific survival (DSS) and relapse free survival (RFS) in breast cancer. And the expression level of ITPR1 was higher in patients treated with chemotherapy than untreated patients. In addition, the expression of ITPR1 was positively correlated with related gene markers of immune cells in different types of breast cancer, especially with BRCA basal tissue breast cancer.
CONCLUSIONS: ITPR1 was lower expressed in breast cancer. The higher expression of ITPR1 suggested favorable prognosis for patients. ITPR1 was related to the level of immune infiltration, especially in BRCA-Basal patients. All research results indicated that ITPR1 might affect breast cancer prognosis and participate in immune regulation. In short, ITPR1 might be a potential target for breast cancer therapy.
摘要：
背景：ITPR1是自噬的关键基因，但其生物学功能尚不清楚,ITPR1基因表达与乳腺癌发生发展的相关性研究较少。
方法：通过Oncomine和TIMER等在线数据库分析ITPR1的表达。Kaplan-Meier绘图仪和其他数据库用于评估ITPR1对临床预后的影响。免疫组化法检测145例乳腺癌组织和30例癌旁正常组织中ITPR1的表达。统计分析用于评估异常表达蛋白的临床相关性和预后意义。并应用WesternBlot检测乳腺癌组织和细胞间ITPR1的表达。TIMER数据库研究了ITPR1与癌症免疫浸润之间的关系。并使用ROC绘图仪数据库预测ITPR1对化疗的反应，乳腺癌患者的内分泌治疗和抗HER2治疗。
结果：与正常乳腺样本相比，ITPR1在乳腺癌患者中显著降低。ITPR1mRNA表达的增加与总生存期（OS）延长密切相关，无远处转移生存期（DMFS），乳腺癌的疾病特异性生存率（DSS）和无复发生存率（RFS）。化疗患者ITPR1的表达水平高于未治疗患者。此外,不同类型乳腺癌组织中,ITPR1的表达与免疫细胞相关基因标记物呈正相关,尤其是BRCA基底组织乳腺癌。
结论：ITPR1在乳腺癌中表达较低。ITPR1的高表达提示患者预后良好。ITPR1与免疫浸润水平有关，尤其是在BRCA基础患者中。所有研究结果表明，ITPR1可能影响乳腺癌的预后并参与免疫调节。总之,ITPR1可能是乳腺癌治疗的潜在靶点。
方法：通过Oncomine和TIMER等在线数据库分析ITPR1的表达。Kaplan-Meier绘图仪和其他数据库用于评估ITPR1对临床预后的影响。免疫组化法检测145例乳腺癌组织和30例癌旁正常组织中ITPR1的表达。统计分析用于评估异常表达蛋白的临床相关性和预后意义。并应用WesternBlot检测乳腺癌组织和细胞间ITPR1的表达。TIMER数据库研究了ITPR1与癌症免疫浸润之间的关系。并使用ROC绘图仪数据库预测ITPR1对化疗的反应，乳腺癌患者的内分泌治疗和抗HER2治疗。
结果：与正常乳腺样本相比，ITPR1在乳腺癌患者中显著降低。ITPR1mRNA表达的增加与总生存期（OS）延长密切相关，无远处转移生存期（DMFS），乳腺癌的疾病特异性生存率（DSS）和无复发生存率（RFS）。化疗患者ITPR1的表达水平高于未治疗患者。此外,不同类型乳腺癌组织中,ITPR1的表达与免疫细胞相关基因标记物呈正相关,尤其是BRCA基底组织乳腺癌。
结论：ITPR1在乳腺癌中表达较低。ITPR1的高表达提示患者预后良好。ITPR1与免疫浸润水平有关，尤其是在BRCA基础患者中。所有研究结果表明，ITPR1可能影响乳腺癌的预后并参与免疫调节。总之,ITPR1可能是乳腺癌治疗的潜在靶点。
